関連する実験動画

Updated: May 5, 2026

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

マクロファージDGKζ媒介によるリン酸再構成は急性肝不全を悪化させる

Yumeng Miao^1,2, Tzuchun Lin¹, Bianlin Wang³

¹Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Acta pharmaceutica Sinica. B

|September 2, 2025

まとめ

新しい化合物であるCAM12203は,マクロファージの炎症を抑制することで,急性肝不全 (ALF) を効果的に治療します. 炎症経路における重要な酵素であるダイアシルグリセロールキナーゼゼタ (DGKζ) を標的にし,ALFに対する有望な治療戦略を提供します.

科学分野:

免疫学と炎症
ヘパトロジーと肝臓疾患
薬理学と薬剤発見

背景:

急性肝不全 (ALF) はマクロファージ媒介の炎症によって引き起こされる重大な状態で,治療の選択肢は限られている.
ALFの既存の治療法は不十分であり,主要な炎症経路を標的とした新しい治療薬の開発が必要である.

研究の目的:

CAM12203の治療の可能性を調査し,ALFを緩和する.
ALFに関連する炎症を減らすために,CAM12203の分子標的と作用機構を特定する.

主な方法:

リポポリサッカリド (LPS) + d- ギャラクトサミン (D- GalN) 誘発ALFモデル in vivo
LC-MS/MSと組み合わせたバイオチンラベリングによるプルダウン測定法で,CAM12203の直接標的を特定する.
ダイアシルグリセロールキナーゼゼタ (DGKζ) - STAT3-インタールイキン-1β (IL-1β) 信号経路の分析.

主要な成果:

CAM12203は,マクロファージ媒介の炎症,特にIL- 1βの転写を抑制することによって,LPS + D- GalN誘発のALFを有意に軽減します.
ダイアシルグリセロールキナーゼゼタ (DGKζ) は,CAM12203の直接的な分子標的として特定されました.
CAM12203は,DGKζ- STAT3- IL- 1β軸を阻害し,IL- 1βの生成を減らし,DGKζに依存した方法でALFの進行を改善します.

結論:

CAM12203は,マクロファージにおけるDGKζ- STAT3- IL- 1β炎症経路を標的にすることで,ALFに対する重要な治療の可能性を示しています.
DGKζは,急性肝不全の治療における新しい有望な治療目標です.
CAM12203は,ALFに対する新しい薬の開発のための潜在的な鉛化合物として機能します.

キーワード:

急性肝不全ディアシルグリセロールキナーゼ ζ 炎症インタールイウキン-1β マクロファージリン酸シグナルトランスデューサーとトランスクリプションアクティベーター 3 クサントホモール系

さらに関連する動画

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool

Rapid Depletion of Renal Macrophages using Human CD59/Intermedilysin Cell Ablation Tool

Published on: May 9, 2025

関連する概念動画

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Acute Pancreatitis II: Pathophysiology

Acute Pancreatitis II: Pathophysiology

The pathophysiology of acute pancreatitis centers on injury to pancreatic acinar cells, which initiates a cascade of harmful intracellular events.This injury leads to premature activation of trypsinogen to trypsin in the pancreas. Trypsin then activates other digestive enzymes, such as chymotrypsin, elastase, and phospholipase A2, which begin breaking down pancreatic tissue. The resulting autodigestion causes local inflammation, tissue swelling, hemorrhage, and fat necrosis.Injured acinar cells...